Trial reportJMIR mHealth and uHealth2026
WeChat-Based Intervention for Glycemic Control in Patients With Type 2 Diabetes Mellitus: Multicenter Randomized Controlled Trial.
Trial report in JMIR mHealth and uHealth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China's diabetes epidemic faces critical gaps in glycemic control, with only 50.1% of treated patients achieving hemoglobin A1C (HbA1c) targets in 2021. Conventional interventions struggle with scalability in primary care, particularly for vulnerable populations. Objective: This study aimed to evaluate the use of a WeChat-based health education tool (the WeWalk mini program, the Bayu Health public account, and a WeChat group) for improving glycemic control in community-dwelling patients with type 2 diabetes mellitus. Methods: This multicenter randomized controlled trial enrolled 600 adults with type 2 diabetes from 3 communities in Chongqing, randomly allocating participants 1:1 to either a 12-week WeChat-based intervention (n=300, 50%) or a control group (n=300, 50%) in September 2020. The control group received 4 face-to-face traditional health education sessions, whereas the intervention group participated in a digital program: a 4-week course followed by an 8-week practical implementation. At baseline and 12 weeks after the intervention began, both groups were examined in terms of HbA1c and fasting blood glucose (FBG) as the primary outcomes, as well as variables such as blood lipid profile, blood pressure, and physical fitness-related indexes as secondary outcomes. Longitudinal glycemic control was assessed through triplicate FBG measurements extracted from standardized electronic health records at the 2-year follow-up. Independent t tests or Mann-Whitney U tests were used to assess changes from baseline to follow-up between groups. Results: A total of 92.7% (556/600) of the participants completed the 12-week follow-up visit. The WeChat-based intervention demonstrated superior glycemic control outcomes, with intervention participants achieving a 0.59% greater HbA1c reduction than controls (-0.03% vs 0.56%; P<.001) and significant improvements in FBG levels (-0.69 vs 0.00 mmol/L; Δ=0.69; P=.001). Subgroup analysis revealed that WeChat-based health education was significantly effective in patients with diabetes with a disease duration of <10 years, educational level of junior high school or lower, and annual family income of <CN ¥50,000 (US $7172.10) . These benefits persisted throughout the 2-year follow-up, where the intervention group maintained lower FBG levels (6.87 vs 7.35 mmol/L; P=.001). Conclusions: WeChat-based health education was beneficial for glycemic control in primary health care settings. However, the sustained efficacy and feasibility of this approach require further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.